Skip to content
Screener

Total Equity at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$84.97B+8.3%
Amgen logo
AmgenAMGN
$11.69B+57.4%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$12.75M-62.5%
Vor Biopharma logo
Vor BiopharmaVOR
-$150.42M-328%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$408.73M-30.8%
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
$95.84M+41.8%

Other financials

Income statement

See full
Revenue$396.0K-81.8%
Operating income-$46.5M-40.3%
Net income-$40.8M-38.4%
EPS (diluted)-$0.85-3.7%

Balance sheet

See full
Cash & equivalents$627.7M+6,105%
Total debt$1.4M-2.3%
Total assets$1.2B+258%

Cash flow

See full
Operating cash flow-$28.9M-4.4%
CapEx$10.0K-58.3%
Free cash flow-$28.9M-4.4%

Valuation

See full
Market cap$6.15B+838%
Enterprise value$5.52B+758%

Profitability

See full
Operating margin-4,558.4%-9,354pp
Net margin-4,104.8%-7,304pp
FCF margin-3,561.6%-6,956pp

Returns & leverage

See full
Return on equity-28.6%+3.2pp
Debt / equity0.0×
Current ratio29.3×+13.3×

Where this comes from

Reported directly by Dianthus Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The source filing: Dianthus Therapeutics’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:06 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001690585-26-000022
Line itemMarch 31,2026December 31,2025
Stockholders’ equity:
Preferred stock; $0.001 par value per share; authorized shares – 10,000,000 at March 31, 2026 and December 31, 2025; issued and outstanding – none at March 31, 2026 and December 31, 2025
Common stock; $0.001 par value per share; authorized shares – 150,000,000 at March 31, 2026 and December 31, 2025; issued and outstanding shares –54,582,749 and 43,223,090 at March 31, 2026 and December 31, 2025, respectively5443
Additional paid-in capital1,579,398829,598
Accumulated deficit(377,563)(336,729)
Accumulated other comprehensive (loss)/income(575)489
Total stockholders’ equity1,201,314493,401
Total liabilities and stockholders’ equity$1,246,884$530,922

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Dianthus Therapeutics's total equity?
Dianthus Therapeutics (DNTH) reported total equity of $1.2B in Q1 2026.
How has Dianthus Therapeutics's total equity changed year-over-year?
Dianthus Therapeutics's total equity increased by 265.6% year-over-year, from $328.61M to $1.2B.
What is the long-term trend for Dianthus Therapeutics's total equity?
Over 5 years (2020 to 2025), Dianthus Therapeutics's total equity has grown at a 27.9% compound annual growth rate (CAGR), from $143.91M to $493.4M.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.

Ask your AI about Dianthus Therapeutics's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude